ReviewMetabolic brain disease2015
Improving the translation of animal ischemic stroke studies to humans.
Review in Metabolic brain disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Role of histone deacetylases and sirtuins in the ischaemic stroke: a systematic review and meta-analysis of animal studies.Stroke and vascular neurology · 2026Pooled it
- Reporting quality, effect sizes, and biases for aging interventions: a methodological appraisal of the DrugAge database.npj aging · 2025Article
- Inflammatory Markers and Stroke Outcomes: Lessons From Neutrophil Counts and Antiplatelet Therapy.Journal of the American Heart Association · 2025Article
- A minimally invasive thrombotic model to study stroke in awake mice.Nature communications · 2025Article
- Effects of stem cell therapy on preclinical stroke.Open veterinary journal · 2025Review
- New approach to control ischemic severity ex vivo.Journal of neuroscience methods · 2025Article
- Long-Term Alterations in Motor Skills, Neurogenesis and Astrocyte Numbers following Transient Cerebral Ischemia in Mice.Medicina (Kaunas, Lithuania) · 2024Article
- Minimal Clinically Important Difference of Scales Reported in Stroke Trials: A Review.Brain sciences · 2024Review
- After Ischemic Stroke, Minocycline Promotes a Protective Response in Neurons via the RNA-Binding Protein HuR, with a Positive Impact on Motor Performance.International journal of molecular sciences · 2023Article
- Preclinical models of middle cerebral artery occlusion: new imaging approaches to a classic technique.Frontiers in neurology · 2023Review
- Ischemic Stroke, Lessons from the Past towards Effective Preclinical Models.Biomedicines · 2022Review
- Bridging the Transient Intraluminal Stroke Preclinical Model to Clinical Practice: From Improved Surgical Procedures to a Workflow of Functional Tests.Frontiers in neurology · 2022Article
- Change and predictive ability of circulating immunoregulatory lymphocytes in long-term outcomes of acute ischemic stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- Nanomedicine for Acute Brain Injuries: Insight from Decades of Cancer Nanomedicine.Molecular pharmaceutics · 2021Review
- Endovascular model of ischemic stroke in swine guided by real-time MRI.Scientific reports · 2020Article
- The Local and Peripheral Immune Responses to Stroke: Implications for Therapeutic Development.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- Alkaline phosphatase: a potential biomarker for stroke and implications for treatment.Metabolic brain disease · 2019Review
- Executive (dys)function after stroke: special considerations for behavioral pharmacology.Behavioural pharmacology · 2018Review
- Endovascular Ischemic Stroke Models in Nonhuman Primates.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018Article
- Ischemic stroke: experimental models and reality.Acta neuropathologica · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Despite testing more than 1,026 therapeutic strategies in models of ischemic stroke and 114 therapies in human ischemic stroke, only one agent tissue plasminogen activator has successfully been translated to clinical practice as a treatment for acute stroke. Though disappointing, this immense body of work has led to a rethinking of animal stroke models and how to better translate therapies to patients with ischemic stroke. Several recommendations have been made, including the STAIR recommendations and statements of RIGOR from the NIH/NINDS. In this commentary we discuss additional aspects that may be important to improve the translational success of ischemic stroke therapies. These include use of tissue plasminogen activator in animal studies; modeling ischemic stroke heterogeneity in terms of infarct size and cause of human stroke; addressing the confounding effect of anesthesia; use of comparable therapeutic dosage between humans and animals based on biological effect; modeling the human immune system; and developing outcome measures in animals comparable to those used in human stroke trials. With additional study and improved animal modeling of factors involved in human ischemic stroke, we are optimistic that new stroke therapies will be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.